<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18254">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01828710</url>
  </required_header>
  <id_info>
    <org_study_id>INO-2103-GC</org_study_id>
    <nct_id>NCT01828710</nct_id>
  </id_info>
  <brief_title>Myo-inositol on Human Semen Parameters</brief_title>
  <official_title>Effect of Treatment With Myo-inositol on Human Semen Parameters in Patients Undergoing IVF Cycles</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AGUNCO Obstetrics and Gynecology Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AGUNCO Obstetrics and Gynecology Centre</source>
  <oversight_info>
    <authority>Italy: National Institute of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many clinical evidences suggest that Myo-inositol plays a crucial role in human
      reproduction. Also, it was shown that Myo-inositol concentration in the seminiferous tubules
      was higher than in serum, and interestingly it was increasing through the epididymis and the
      deferent duct mining that sperm cell before ejaculation are stored in a &quot;medium&quot; highly
      enriched in myo-inositol.

      Starting from this evidences, the investigators hypothesized that myo-inositol may be a
      possible factor able to improve the semen parameters of samples used in in vitro
      fertilization cycles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Samples of seminal fluid were obtained from two groups of patients undergoing to an IVF
      cycle: healthy normospermic subjects and subjects with oligoasthenoteratospermia (OAT, &lt; 15
      mil/ml).

      Semen volume, spermatozoa number and motility were evaluated during the initial semen
      analysis and after density gradient separation method. These parameters were evaluated
      before and after the administration of 4000mg/die of myo-inositol associated to 400 µg of
      folic acid (Inofolic lolipharma Rome) for three months.

      A third group of healthy normospermic subject were traded with 400 µg of folic acid for
      three months and was consider a control group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening</study_design>
  <primary_outcome>
    <measure>sperm concentration</measure>
    <time_frame>after 3 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Asthenozoospermia</condition>
  <condition>Oligospermia</condition>
  <arm_group>
    <arm_group_label>Myo-inositol normospermic</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>29 normospermic treated with 4000mg/die of myo-inositol and 400 µg of folic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Myo-inositol OAT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>13 OAT patients treated with 4000mg/die of myo-inositol associated to 400 µg of folic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Folic acid normospermic</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 normospermic patients treated with 400 µg of folic acid</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Myo-inositol normospermic</intervention_name>
    <description>4000mg/die of myo-inositol and 400 µg of folic acid (Inofolic® Lo.Li. pharma s.r.l., Roma) for three months.</description>
    <arm_group_label>Myo-inositol normospermic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Myo-inositol OAT</intervention_name>
    <description>B 13 OAT patients treated with 4000mg/die of myo-inositol associated to 400 µg of folic acid (Inofolic® Lo.Li. pharma s.r.l., Roma) for three months</description>
    <arm_group_label>Myo-inositol OAT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Folic Acid normospermic</intervention_name>
    <description>Group C 20 normospermic patients treated with 400 µg of folic acid (kindly provided by Lo.Li. pharma s.r.l., Roma) for three months.</description>
    <arm_group_label>Folic acid normospermic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Undergoing to IVF cycle OAT

        Exclusion Criteria:

        No undergoing to IVF cycle
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco Palumbo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Catania - Department of Surgery - Section of Obstetrics and Gynecology -  Centre of Physiopathology of Reproduction</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gianfranco Carlomagno, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>A.G.Un.Co. Obstetrics and gynaecology center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre of Physiopathology of Reproduction</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95010</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 10, 2013</lastchanged_date>
  <firstreceived_date>March 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myo-inositol</keyword>
  <keyword>oligoasthenoteratospermia</keyword>
  <keyword>semen parameters</keyword>
  <keyword>IVF</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oligospermia</mesh_term>
    <mesh_term>Asthenozoospermia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
    <mesh_term>Inositol</mesh_term>
    <mesh_term>Hematinics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
